Herbert Chiou, PhD

Herbert Chiou is the Head of CMC at Northlinks Bio.  He is a seasoned CMC leader with deep expertise in respiratory drug delivery and complex biologics, spanning formulation optimization, process science and development, scale‑up, and analytical strategy. He has led teams at 3M Drug Delivery Systems (now Kindeva), Lupin’s Inhalation Research Center, and Lonza, where he drove the establishment of their Center of Excellence for integrated dry‑powder inhaler development.  Herbert also directed formulation, manufacturing, and characterization of lipid nanoparticle–based genetic medicines at Moderna, Generation Bio, and nChroma Bio.  He has advanced programs through first‑in‑human clinical studies, delivered product and data for bioequivalence studies, and supported the development, manufacture, and release of Phase 1 and Phase 2 clinical materials.  He brings a proven record of driving phase‑appropriate CMC activities that enable rapid, high‑quality execution to support NorthLinks Bio's mission.  Herbert obtained both his PhD in Chemistry and Bachelor of Science (Honours I) from The University of Sydney.